公开(公告)号：US20220193136A1

公开(公告)日：2022-06-23

申请号：US17569107

申请日：2022-01-05

申请人： The Regents of the University of California ,  Seattle Children's Hospital DBA Seattle Children's Research Institute

发明人： Yvonne Y. CHEN ,  Eugenia ZAH ,  Michael C. JENSEN

IPC分类号： A61K35/17 ,  C07K16/46 ,  C12N5/0783 ,  C07K16/28 ,  C07K14/725 ,  C07K14/705

摘要： A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.

公开(公告)号：US20210145880A1

公开(公告)日：2021-05-20

申请号：US17028701

申请日：2020-09-22

申请人： The Regents of the University of California ,  Seattle Children's Hospital DBA Seattle Children's Research Institute

发明人： Yvonne Y. CHEN ,  Eugenia ZAH ,  Michael C. JENSEN

IPC分类号： A61K35/17 ,  C07K16/46 ,  C12N5/0783 ,  C07K16/28 ,  C07K14/725 ,  C07K14/705

摘要： A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.

公开(公告)号：US20170368098A1

公开(公告)日：2017-12-28

申请号：US15535972

申请日：2015-12-14

申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  SEATTLE CHILDREN'S HOSPITAL DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE

发明人： Yvonne Y. CHEN ,  Eugenia ZAH ,  Michael C. JENSEN

IPC分类号： A61K35/17 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783 ,  C07K16/46 ,  C07K14/705 ,  A61K39/00 ,  A61K38/00

CPC分类号： A61K35/17 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/70596 ,  C07K16/2803 ,  C07K16/2887 ,  C07K16/46 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2319/03 ,  C07K2319/40 ,  C12N5/0636 ,  C12N2510/00

摘要： A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.

公开(公告)号：US20210230289A1

公开(公告)日：2021-07-29

申请号：US17251287

申请日：2019-06-12

申请人： The Regents of the University of California

发明人： Yvonne Yu-hsuan CHEN ,  Eugenia ZAH

IPC分类号： C07K16/28 ,  C07K14/705 ,  C07K14/725 ,  C12N15/86 ,  C12N5/0783 ,  A61P35/00 ,  A61K35/17 ,  A61K38/17

摘要： Methods and compositions are provided concerning a bispecific chimeric antigen receptor (CAR) targeting BCMA and CS1, particularly in multiple myeloma patients. The bispecific CAR has advantages over dual or separate BCMA and CS1 CAR molecules. In some embodiments, there is a bispecific chimeric antigen receptor comprising a) a bispecific extracellular binding domain comprising both i) a BCMA-binding region and ii) a CSI-binding region; b) a single transmembrane domain; and, c) a single cytoplasmic region comprising a primary intracellular signaling domain.